The clinical presentation of dermatitis artefacta is often strikingly atypical. Lesions may appear bizarre, geometric, or linear, and they rarely follow the patterns expected of known dermatoses. Excoriations, ulcers, blisters, burns, contact dermatitis, hematomas, and hyperpigmentation have all been described, and the variety of appearances can be so creative that the condition has been called a great imitator of ordinary skin disease. One of the most useful diagnostic clues is anatomic: lesions cluster on easily accessible body areas such as the face, neck, upper limbs, and trunk, often within reach of the dominant hand. Another hallmark is what the literature calls a hollow history, in which mature-appearing lesions are present at first assessment without any documented progression or evolutionary change, suggesting they did not arise through a typical disease process.

Diagnosis is frequently delayed, and the reasons are structural as much as clinical. Because patients conceal the self-inflicted nature of their injuries and may fear being named and shamed, dermatologists often order repeated investigations and trials of treatment before the factitious origin is even considered. The true prevalence of the condition remains unknown, since non-disclosure and clinical variability make population estimates nearly impossible. Cases have been reported across all ages, genders, and backgrounds, but the disorder is most frequently observed in adolescent and adult females, with estimated female-to-male ratios ranging from 4:1 to as high as 20:1. The review cautions that this skew likely reflects small retrospective case series, differing diagnostic criteria, referral bias, and underrecognition in certain populations rather than a settled epidemiologic picture.

What is increasingly clear is that dermatitis artefacta rarely occurs in psychological isolation. The condition arises from multifactorial causes, often rooted in psychiatric comorbidity and emotional distress, and the self-inflicted lesions frequently function as a maladaptive coping mechanism for internal pain, unresolved trauma, or unmet emotional needs that the patient may only dimly perceive. Some individuals injure themselves during dissociative episodes, while others act more deliberately yet still deny awareness or responsibility. Substance use is more common among affected patients and may amplify impulsivity and emotional dysregulation. In a retrospective review of 28 patients managed in a multidisciplinary psychodermatology clinic cited in the new paper, 46 percent had a concomitant mental health disorder at presentation, with anxiety, depression, and personality disorders representing the most frequently identified diagnoses.

Borderline personality disorder deserves particular attention in this context. It has been reported in patients with dermatitis artefacta and may contribute to the emotional dysregulation and impulsivity that complicate clinical management, although the review stresses that its specific prevalence remains uncertain and that it should be considered one of several possible comorbidities rather than a defining feature of the disorder. Complex life histories, including early trauma and chronic stress, are common antecedents, and coexisting chronic dermatologic or medical conditions can further obscure the diagnosis, especially when wounds heal slowly or psychiatric symptoms are subtle. For such patients, the authors argue, multidisciplinary care is not optional but essential to address both the physical lesions and the psychological distress driving them.

Distinguishing dermatitis artefacta from its psychiatric and dermatologic mimics is a technical exercise with real therapeutic consequences. Neurotic excoriations involve compulsive skin picking, often secondary to obsessive-compulsive disorder or anxiety, but unlike dermatitis artefacta patients typically acknowledge their behavior. Delusional parasitosis produces similar self-inflicted lesions, sometimes accompanied by the so-called matchbox sign in which patients present fragments of skin or debris as evidence of infestation, yet the driver is a fixed delusional belief rather than a voluntary behavior aimed at assuming the sick role. Malingering involves self-injury for clear external incentives such as financial gain, whereas Munchausen syndrome, the severe form of factitious disorder, involves intentional symptom production across multiple organ systems rather than the purely cutaneous manifestations of dermatitis artefacta. Body dysmorphic disorder, meanwhile, drives excessive grooming and picking through preoccupation with perceived appearance flaws. Because dermatitis artefacta can imitate eczema, psoriasis, and acne, thorough clinical evaluation and detailed history-taking remain indispensable.

The management philosophy that emerges from the review is unambiguous: dermatologic treatment alone is rarely successful, and confrontation about the origin of lesions tends to backfire. Open confrontation may provoke anger, shame, or outright disengagement from care, and patients who feel accused often simply move on to another provider, fragmenting their treatment and restarting the diagnostic cycle. Instead, the authors advocate a non-confrontational, patient-centered approach grounded in empathy, trust-building, and consistency, framed within a biopsychosocial model in which dermatologists, psychiatrists, and psychologists collaborate. Shame, self-stigma, and fear of social rejection are common across psychocutaneous disorders and contribute to avoidance behaviors and diminished quality of life, which makes the tone of the first clinical encounter disproportionately important to long-term outcomes.

Once rapport is established, structured psychiatric screening gives dermatologists an accessible entry point into mental health assessment. The Patient Health Questionnaire-9 and the Generalized Anxiety Disorder 7-item scale are validated, brief tools for identifying depressive and anxiety symptoms, while the Dissociative Experiences Scale provides a quantified measure for patients with trauma histories or dissociative features. When a formal psychiatric referral is warranted, the way it is introduced matters enormously, because patients may interpret it as dismissive of their physical complaints. The review suggests framing the referral around the well-documented overlap between chronic inflammatory skin disease and mental health disorders, positioning psychiatric care as a strategy to improve both skin and mind rather than as a verdict that the problem is all in the patient’s head.

Treatment itself must be individualized, and the review is candid about the limits of the evidence base: recommendations rest primarily on case reports, case series, and expert opinion, because controlled clinical trials in dermatitis artefacta are scarce. Cognitive behavioral therapy may help address mood and anxiety disorders and reduce maladaptive coping mechanisms such as skin manipulation. Acceptance-enhanced behavior therapy may suit patients with mood dysregulation, with reports of reduced self-initiated cutaneous injuries and improved psychological functioning. For those with trauma histories or dissociative symptoms, eye movement desensitization and reprocessing has been associated with sustained dermatologic improvement and emotional resolution of trauma-induced distress. Psychodynamic therapy may benefit patients whose depression, trauma, or anxiety is prominent, and case reports describe its usefulness in adjacent body-focused repetitive behaviors such as trichotillomania and nail biting. When psychotherapy alone is insufficient and psychiatric comorbidity causes significant morbidity, pharmacologic options come into play: selective serotonin reuptake inhibitors are favored for their efficacy in depression and anxiety and their favorable side effect profile, while case reports suggest mood stabilizers may reduce dissociative episodes and self-harm in patients with underlying affective or personality disorders.

The review closes with a sober assessment of what the field still lacks. No controlled trials exist, standardized diagnostic approaches are missing, and heterogeneous presentations continue to delay recognition, so the authors call for prospective multicenter studies, better characterization of psychiatric comorbidities, and formal evaluation of multidisciplinary psychodermatology care models. In the meantime, the practical message for clinicians is that effective management extends well beyond the resolution of skin lesions. Long-term follow-up should monitor psychiatric symptoms, psychosocial stressors, treatment adherence, and recurrence, with timely adjustment of therapy as circumstances change. Relapse is common, and the single most protective factor appears to be a sustained, trust-based therapeutic relationship that accommodates patients through the fluctuating course of this psychologically driven condition. Recognizing dermatitis artefacta as fundamentally psychocutaneous, and integrating dermatologic and psychiatric care from the first suspicion through years of follow-up, may be the difference between a patient lost to repeated referrals and one who finally begins to heal.

Subject of Research: Psychiatric comorbidities and treatment strategies in dermatitis artefacta, a factitious psychodermatologic disorder

Article Title: Psychiatric comorbidities and treatment strategies in dermatitis artefacta: a narrative review

Article References: Park, I., Bayrouti, A., MacIntyre, D., Awad, C., & Nguyen, M. O. (2026). Psychiatric comorbidities and treatment strategies in dermatitis artefacta: a narrative review. Archives of Dermatological Research, 318(1), Article 479. https://doi.org/10.1007/s00403-026-04973-1

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04973-1

Keywords: dermatitis artefacta, psychodermatology, factitious disorder, psychiatric comorbidities, self-inflicted skin lesions, cognitive behavioral therapy, SSRIs, EMDR, borderline personality disorder, mood stabilizers, psychodynamic therapy, multidisciplinary care

The review, led by Qing Huang and colleagues, synthesizes epidemiological data, neuroimaging findings, electrophysiological studies, and treatment reports to build an integrated framework for the syndrome. Its central claim is provocative: the anxiety, depression, depersonalization, fatigue, and sleep disturbances that so often accompany visual snow may not simply be psychological reactions to a chronic and distressing symptom. Instead, they may be intrinsic expressions of the same underlying neurobiology, reflecting dysfunction in the shared circuits that govern perception, emotion regulation, and salience attribution. This reframing has significant implications for how clinicians diagnose, investigate, and ultimately treat the disorder.

Epidemiologically, visual snow syndrome appears to be far from rare. Cross-sectional studies conducted in Italy, the United Kingdom, and Russia have estimated prevalence at between 0.7 and 4.4 percent, using symptom-based screening questionnaires followed by clinical validation. An online survey found that 41.9 percent of respondents had experienced visual snow phenomena at some point, yet only 4.49 percent met the full diagnostic criteria of the International Classification of Headache Disorders, third edition. Most affected individuals screened in prevalence studies had never received a formal diagnosis before enrollment, underscoring how frequently the condition escapes clinical recognition. Cohorts typically show a female predominance and a mean age of roughly 25 to 30 years, although one large study of more than 1,100 patients found no significant sex difference and a mean age of 29.

Onset patterns are strikingly variable. Reported proportions of childhood-onset cases, in which symptoms have been present for as long as the patient can remember, range from 17.2 percent in a hospital-based outpatient study to 89.6 percent in an online survey, with two large cohorts suggesting approximately 40 percent. The review cautions that this phrase should not be equated with a truly congenital condition, although the data raise the possibility of a genetically predisposed congenital subtype whose true prevalence remains unknown. In other patients, onset follows a precipitating event: 42.3 percent of patients in one study reported a triggering event or associated comorbidity. Migraine is the most common, affecting roughly 50 to 70 percent of patients, and the likelihood of developing the syndrome is significantly elevated among people with migraine. Case reports implicate occipital ischemic stroke, hallucinogen persisting perception disorder associated with substances such as LSD and delta-8-tetrahydrocannabinol, selective serotonin reuptake inhibitor exposure, mild traumatic brain injury, infection, idiopathic intracranial hypertension, and ocular abnormalities. The emerging picture is of a disorder triggered by multiple environmental or pathological factors in genetically susceptible individuals.

The mechanistic evidence reviewed by the authors is where the network concept gains its force. Ultra-high-field 7 Tesla structural MRI has revealed that, despite the absence of gross morphometric abnormalities, patients show reduced T1 values following a clear caudorostral gradient, most pronounced in the occipital cortex and diminishing toward parietal, temporal, and prefrontal regions. Significant T1 reductions across multiple thalamic nuclei suggest alterations in neuronal density, membrane integrity, or microstructural organization, while voxel-based morphometry has documented increased gray matter volume at the right lingual gyrus–fusiform gyrus junction and in temporal and limbic lobes, alongside reduced volume in the superior temporal gyrus. Together, these findings map a distributed visual–thalamic–limbic architecture rather than a single lesioned locus.

Functional studies reinforce this distributed view. Magnetoencephalography has demonstrated increased gamma-band power in the primary visual cortex, a signature of cortical hyperexcitability, together with reduced alpha-phase-to-gamma-amplitude coupling, indicating impaired top-down inhibitory modulation from higher-order visual areas. Resting-state EEG shows reduced alpha-band power spectral density in the parietotemporal region, corresponding to secondary visual cortex dysfunction, and abnormally enhanced activity-dependent neuroplasticity has also been reported. Positron emission tomography reveals hypermetabolism in the right extrastriate cortex accompanied by hypometabolism in temporoparietal regions involved in auditory processing and attentional control. Functional MRI demonstrates abnormal connectivity within the visual network and disrupted connections involving the thalamus, basal ganglia, default mode network, and salience-attention systems, both at rest and during stimulation. EEG microstate analyses add evidence of unstable large-scale network dynamics, with reduced microstate duration and amplitude and abnormal transitions among auditory–visual, visual, and salience-related states. In this model, patients cannot effectively suppress internally generated visual noise, allowing it to enter conscious awareness as continuous static.

Crucially, the same circuitry offers a bridge to the psychiatric dimension. Neuroimaging has identified increased gray matter volume in bilateral limbic structures, including the anterior cingulate cortex, insula, and prefrontal cortex, along with hypometabolism in the hippocampal–parahippocampal region. Reduced parahippocampal–occipital connectivity correlates significantly with subjective distress, suggesting disruption of a perception–emotion–inhibition loop. Receptor-enriched connectivity analyses point to abnormalities in glutamatergic and serotonergic pathways within the anterior cingulate, insula, orbitofrontal cortex, and visual association areas. Notably, psychiatric symptom severity does not differ between childhood-onset and later-onset patients, and longitudinal studies show that anxiety and depressive symptoms remain stable over time, patterns more consistent with shared neurobiology than with purely reactive distress. Familial aggregation adds a genetic dimension: 2.4 to 10 percent of first-degree relatives are affected, and migraine prevalence among relatives ranges from 9.4 to 56 percent, hinting at shared vulnerability, though no genome-wide association or linkage studies have yet been performed.

The clinical burden is substantial. Depressive symptoms affect between 14.1 and 53 percent of patients depending on the instrument and design, while anxiety symptoms range from 15.4 to 49 percent; longitudinal assessments found lifetime rates of 41.4 percent for depression and 44.8 percent for anxiety, and symptom severity correlates with visual symptom severity. Approximately 45 percent of patients experience depersonalization, with a quarter reaching clinical threshold. Sleep is frequently disrupted, with 44.8 percent reporting difficulty initiating sleep due to visual interference in darkness, and 49.6 percent meeting criteria for clinically significant fatigue. Quality of life is markedly impaired across mental health, social functioning, and role-emotional domains, and recent work shows that self-efficacy and quality of life sequentially mediate the relationship between symptom burden and adverse outcomes including depression and suicidal ideation, identifying psychosocial mechanisms as actionable intervention targets.

Treatment remains the weakest link. Pharmacological options are largely empirical and modestly effective: lamotrigine produced partial improvement in 19.2 percent of patients in one study with no complete remissions and adverse reactions in half of users, while topiramate response rates range from 15.4 to 28.5 percent. A survey of 400 patients found that antidepressants, antiepileptic drugs, antibiotics, and benzodiazepines were generally ineffective and often poorly tolerated. By contrast, non-pharmacological approaches show encouraging preliminary signals. Tinted lenses, particularly yellow and blue spectral filters, reduce the intensity, duration, and frequency of visual snow in 80 to 92 percent of individuals and improve palinopsia and photophobia by roughly 50 percent on average. Repetitive transcranial magnetic stimulation targeting the visual cortex or bilateral lingual gyri has shown favorable safety and preliminary efficacy, and prolonged exposure to high-contrast dynamic visual noise can reduce or temporarily eliminate symptoms. Mindfulness-based cognitive therapy has demonstrated dual benefits for visual symptoms and psychological distress, plausibly by modulating visual network connectivity through enhanced attentional flexibility and non-reactive awareness. Patients also report that darkness, bright light, stress, alcohol, sleep deprivation, and prolonged screen exposure worsen symptoms, while adequate sleep, stress reduction, meditation, and regular exercise help.

The review’s authors are careful to note that much of the current evidence derives from cross-sectional, retrospective, or uncontrolled studies, so causal relationships among visual symptoms, network dysfunction, and psychiatric manifestations must be interpreted cautiously. Yet the convergence of structural, functional, electrophysiological, and neurochemical findings on a single integrated model is difficult to ignore. They call for multidisciplinary research integrating neurology, psychiatry, neuroimaging, electrophysiology, and genetics, including Mendelian randomization, polygenic risk scoring, and multi-omics approaches, to identify biomarkers linking symptom dimensions to specific network and molecular alterations. For a condition that affects as many as one in twenty-five people by some estimates yet remains routinely missed, recognizing visual snow syndrome as a genuine neuropsychiatric network disorder may be the first step toward precision diagnosis and, eventually, effective therapy.

Subject of Research: Visual snow syndrome as a neuropsychiatric network disorder involving visual cortical hyperexcitability, thalamocortical dysrhythmia, and limbic dysfunction

Article Title: Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives

Article References: Huang, Q., Wang, J., Zhao, L., Yu, X., Wang, W., Wang, Z., & Liu, Y. (2026). Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives. Journal of Neurology, 273(10), Article 610. https://doi.org/10.1007/s00415-026-14137-w

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14137-w

Keywords: visual snow syndrome, neuropsychiatric disorders, thalamocortical dysrhythmia, functional connectivity, migraine, depersonalization, neuroimaging, transcranial magnetic stimulation, tinted lenses, mindfulness-based cognitive therapy, anxiety, depression